Profound Medical Corp.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
PROF$7.68+4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders’ Equity (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · Accumulated · · | ||||||||||||
| | | | | | | Additional | | Other | | | | |
| | | | | | | Paid-in | | Comprehensive | | Accumulated | | |
| · · Common Shares · · Capital · · Income · · Deficit · · Tota1 | ||||||||||||
| | | Shares | | Amount $ | | $ | | $ | | $ | | $ |
| Balance - December 31, 2024 | 30,039,809 | 281,552 | 21,298 | 2,742 | (245,170) | 60,422 | ||||||
| | | | | | | | | | | | | |
| Net loss for the period | — | — | — | — | (10,724) | (10,724) | ||||||
| Cumulative translation adjustment – net of tax of $nil | — | — | — | 103 | — | 103 | ||||||
| Vesting of RSUs (note 10) | | 13,333 | | 89 | | (89) | | — | | — | | — |
| Share-based compensation (note 10) | — | — | 989 | — | — | 989 | ||||||
| Balance – March 31, 2025 | 30,053,142 | 281,641 | 22,198 | 2,845 | (255,894) | 50,790 | ||||||
| | | | | | | | | | | | | |
| Net loss for the period | — | — | — | — | (15,695) | (15,695) | ||||||
| Cumulative translation adjustment – net of tax of $nil | — | — | — | 2,713 | — | 2,713 | ||||||
| Share-based compensation (note 10) | — | — | 1,451 | — | — | 1,451 | ||||||
| Balance – June 30, 2025 | 30,053,142 | 281,641 | 23,649 | 5,558 | (271,589) | 39,259 | ||||||
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · Accumulated · · · | ||||||||||||
| · · · · · · Additional · · Other · · · | ||||||||||||
| · · · · · · Paid-in · · Comprehensive · · Accumulated · | ||||||||||||
| · · Common Shares · · Capital · · Income · · Deficit · · Total | ||||||||||||
| | | Shares | | Amount $ | | $ | | $ | | $ | | $ |
| Balance - December 31, 2023 | 21,370,565 | 222,205 | 20,808 | 5,565 | (217,354) | 31,224 | ||||||
| | | | | | | | | | | | | |
| Net loss for the period | — | — | — | — | (6,585) | (6,585) | ||||||
| Cumulative translation adjustment – net of tax of $nil | — | — | — | (969) | — | (969) | ||||||
| Shares issued in public offering and private placement | 3,058,334 | 21,079 | — | — | — | 21,079 | ||||||
| Share-based compensation (note 10) | — | — | 767 | — | — | 767 | ||||||
| Balance – March 31, 2024 | 24,428,899 | 243,284 | 21,575 | 4,596 | (223,939) | 45,516 | ||||||
| | | | | | | | | | | | | |
| Net loss for the period | | — | | — | | — | | — | | (6,919) | | (6,919) |
| Cumulative translation adjustment – net of tax of $nil | | — | | — | | — | | (470) | | — | | (470) |
| Exercise of share options (note 10) | | 101 | | 1 | | (1) | | — | | — | | — |
| Vesting of RSUs (note 10) | | 52,835 | | 413 | | (413) | | — | | — | | — |
| Share-based compensation (note 10) | | — | | — | | 768 | | — | | — | | 768 |
| Balance – June 30, 2024 | | 24,481,835 | | 243,698 | | 21,929 | | 4,126 | | (230,858) | | 38,895 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.